Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan 15;9(1):e85774.
doi: 10.1371/journal.pone.0085774. eCollection 2014.

Determinants of mortality and loss to follow-up among adults enrolled in HIV care services in Rwanda

Affiliations

Determinants of mortality and loss to follow-up among adults enrolled in HIV care services in Rwanda

Veronicah Mugisha et al. PLoS One. .

Erratum in

  • PLoS One. 2014;9(2):e91626

Abstract

Background: Antiretroviral therapy (ART) improves morbidity and mortality in patients with HIV, however high rates of loss to follow-up (LTF) and mortality have been documented in HIV care and treatment programs.

Methods: We analyzed routinely-collected data on HIV-infected patients ≥ 15 years enrolled at 41 healthcare facilities in Rwanda from 2005 to 2010. LTF was defined as not attending clinic in the last 12 months for pre-ART patients and 6 months for ART patients. For the pre-ART period, sub-distribution hazards models were constructed to estimate LTF and death to account for competing risks. Kaplan-Meier (KM) and Cox proportional hazards models were used for patients on ART.

Results: 31,033 ART-naïve adults were included, 64% were female and 75% were WHO stage I or II at enrollment. 17,569 (56%) patients initiated ART. Pre-ART competing risk estimates of LTF at 2 years was 11.2% (95%CI, 10.9-11.6%) and 2.9% for death (95%CI 2.7-3.1%). Among pre-ART patients, male gender was associated with higher LTF (adjusted sub-hazard ratio (aSHR) 1.3, 95%CI 1.1-1.5) and death (aSHR 1.7, 95%CI 1.4-2.1). Low CD4 count (CD4<100 vs. ≥ 350 aSHR 0.2, 95%CI 0.1-0.3) and higher WHO stage (WHO stage IV vs. stage I aSHR 0.4, 95%CI 0.2-0.6) were protective against pre-ART LTF. KM estimates for LTF and death in ART patients at 2 years were 4.4% (95%CI 4.4-4.5%) and 6.3% (95%CI 6.2-6.4%). In patients on ART, male gender was associated with LTF (adjusted hazard ratio (AHR) 1.4, 95%CI 1.2-1.7) and death (AHR1.3, 95%CI 1.2-1.5). Mortality was higher for ART patients ≥ 40 years and in those with lower CD4 count at ART initiation.

Conclusions: Low rates of LTF and death were founds among pre-ART and ART patients in Rwanda but greater efforts are needed to retain patients in care prior to ART initiation, particularly among those who are healthy at enrollment.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Cumulative incidence of LTF and mortality among pre-ART adult patients in Rwanda (N = 31,033).
Patients were counted as LTF starting at 90 days after the enrollment visit, as a result the cumulative incidence for LTF starts at this point rather than time 0 on figure.
Figure 2
Figure 2. Kaplan-Meier estimates of LTF and mortality among adults on ART in Rwanda (N = 17,212).

Similar articles

Cited by

References

    1. UNAIDS (2012) World AIDS Day Report Geneva, Switzerland: UNAIDS.
    1. Lowrance DW, Ndamage F, Kayirangwa E, Ndagije F, Lo W, et al. (2009) Adult clinical and immunologic outcomes of the national antiretroviral treatment program in Rwanda during 2004–2005. Journal of acquired immune deficiency syndromes 52: 49–55. - PubMed
    1. Rwanda MoH (2011) Annual report July 2010 - June 2011. Kigali, Rwanda: Government of Rwanda.
    1. WHO (2011) Global HIV/AIDS Response: Epidemic update and health sector progress towards Universal Access. In: HIV/AIDS, editor editors. Geneva, Switzerland: World Health Organization.
    1. (2006) Human Resources for Health Strategic Plan 2006–2010. In: R. Ministry of Health, editor editors. Kigali, Rwanda: Government of Rwanda.

Publication types

Substances